Akari Therapeutics (AKTX) Interest Expenses (2011 - 2026)

Akari Therapeutics (AKTX) has reported Interest Expenses for 14 consecutive years, with $100000.0 the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses changed 0.0% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $201000.0 (down 99.29% YoY) and the FY2025 annual result came in at $63.4 million, up 5.0% from the prior year.
• Interest Expenses climbed to $100000.0 in Q1 2026 per AKTX's latest filing, from $1000.0 in the prior quarter.
• Over the last five years, Interest Expenses for AKTX reached as high as $42.2 million in Q4 2023 and fell as low as $1000.0 in Q3 2025.
• A 5-year average of $11.7 million and a median of $100000.0 in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses gained 22.03% — and 2025, when it slumped 98.55%.
• Year by year, Interest Expenses stood at $34.6 million in 2022, then climbed by 22.03% to $42.2 million in 2023, then plunged by 33.7% to $28.0 million in 2024, then sank by 100.0% to $1000.0 in 2025, then soared by 9900.0% to $100000.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $100000.0, $1000.0, and $100000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.